



Substitute for Form 1449A/PTO  
(Modified)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/734,689
Filing Date	December 11, 2003
First Named Inventor	Mark A. Gallop
Art Unit	1614
Examiner Name	Not Assigned
Attorney Docket Number	34470/US/3/AMP/SKS (459258-00003)

Sheet 1 of 3

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
B/D	A1	3,845,770	11-05-1974	Theeuwes <i>et al.</i>	
B/D	A2	3,916,899	11-04-1975	Theeuwes <i>et al.</i>	
B/D	A3	4,024,175	05-17-1977	Satzinger <i>et al.</i>	
B/D	A4	4,087,544	05-02-1978	Satzinger <i>et al.</i>	
B/D	A5	5,084,169	01-28-1992	Woodruff	
B/D	A6	5,112,598	05-02-1992	Biesalski	
B/D	A7	5,556,611	09-17-1996	Biesalski	
B/D	A8	5,563,175	10-08-1996	Silverman <i>et al.</i>	
B/D	A9	5,698,155	12-16-1997	Grosswald <i>et al.</i>	
B/D	A10	6,001,876	12-14-1999	Singh	
B/D	A11	6,020,370	02-01-2000	Horwell <i>et al.</i>	
B/D	A12	6,028,214	02-22-2000	Silverman <i>et al.</i>	
B/D	A13	6,103,932	08-15-2000	Horwell <i>et al.</i>	
B/D	A14	6,117,906	09-12-2000	Silverman <i>et al.</i>	
B/D	A15	6,596,900	07-22-2003	Blakemore <i>et al.</i>	
B/D	A16	10/171,485		Gallop <i>et al.</i>	
B/D	A17	10/170,127		Cundy <i>et al.</i>	
B/D	A18	10/167,797		Gallop <i>et al.</i>	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1 <sup>6</sup>
B/D	B1	WO 92/09560 A1	06-11-1992	Silverman,		
B/D	B2	WO 93/23383 A1	11-25-1993	Silverman <i>et al.</i>		
B/D	B3	WO 97/29101 A1	08-14-1997	Horwell <i>et al.</i>		
B/D	B4	WO 97/33858 A1	09-18-1997	Horwell <i>et al.</i>		
B/D	B5	WO 97/33859 A1	09-18-1997	Horwell <i>et al.</i>		
B/D	B6	WO 98/17627 A1	04-30-1998	Bryans <i>et al.</i>		
B/D	B7	WO 99/08671 A1	02-25-1999	Guglietta <i>et al.</i>		
B/D	B8	WO 99/21824 A1	05-06-1999	Bryans <i>et al.</i>		

Examiner Signature		Date Considered	6-16-2005
--------------------	--	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/734,689
				Filing Date	December 11, 2003
				First Named Inventor	Mark A. Gallop
				Group Art Unit	1614
				Examiner Name	Not Assigned
Sheet	2	of	3	Attorney Docket Number	34470/US/3/RFT/SKS (459258-00003)

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
B9	B9	WO 99/31057 A1	06-24-1999	Bryans <i>et al.</i>		
B10	B10	WO 99/31074 A2/A3	06-24-1999	Belliotti <i>et al.</i>		
B11	B11	WO 99/31075 A1	06-24-1999	Bryans <i>et al.</i>		
B12	B12	WO 99/37296 A1	07-29-1999	Magnus-Miller <i>et al.</i>		
B13	B13	WO 99/61424 A1	12-02-1999	Bryans <i>et al.</i>		
B14	B14	WO 00/31020 A1	06-02-2000	Bryans		
B15	B15	WO 00/23067 A1	04-27-2000	Pande		
B16	B16	WO 00/50027 A1	08-31-2000	Bryans <i>et al.</i>		
B17	B17	WO 01/28978 A1	04-26-2001	Bryans <i>et al.</i>		
B18	B18	WO 02/00209 A2/A3	01-03-2002	Bryans <i>et al.</i>		
B19	B19	WO 00/15611 A1	03-23-2002	Bryans <i>et al.</i>		
B20	B20	WO 02/085839 A1	10-31-2002	Blakemore <i>et al.</i>		
B21	B21	WO 02/090318 A1	11-14-2002	Blakemore <i>et al.</i>		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
B1	C1	Alderman, "A Review of Cellulose Ethers in Hydrophilic Matrices or Oral controlled-Release Dosage Forms," <i>Int. J. Pharm. Tech. &amp; Prod. Mfr.</i> 1984, 5(3) 1-9.				
B2	C2	Bamba <i>et al.</i> , "Release Mechanisms in Gelforming Sustained Release Preparations," <i>Int. J. Pharm.</i> 1979, 2, 307.				
B3	C3	Bryans <i>et al.</i> , "3-Substituted GABA Analogs with Central Nervous System Activity: A Review," <i>Med. Res. Rev.</i> 1999, 19, 149-177				
B4	C4	During <i>et al.</i> , "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," 1989, <i>Ann. Neurol.</i> 25:351.				
B5	C5	Goodson, "Medical Applications of Controlled Release," vol. 2, pp. 115-138 (1984).				
B6	C6	Howard <i>et al.</i> , "Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," 1989, <i>J. Neurosurg.</i> 71:105-112.				
B7	C7	Jezyk <i>et al.</i> , "Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers," <i>Pharm. Res.</i> 1999, 16, 519-526.				

Examiner Signature		Date Considered	6-16-2005
--------------------	--	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/734,689	
			Filing Date	December 11, 2003	
			First Named Inventor	Mark A. Gallop	
			Group Art Unit	1614	
			Examiner Name	Not Assigned	
Sheet	3	of	3	Attorney Docket Number	34470/US/3/RFT/SKS (459258-00003)

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Citation No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
B/D	C8	Langer <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J Macromol. Sci. Rev. Macromol Chem.</i> 1983, 23:61.
B/D	C9	Langer, "New Method of Drug Delivery," 1990, <i>Science</i> 249:1527-1533.
B/D	C10	Levy <i>et al.</i> , "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> 1985 228: 190-192.
B/D	C11	Magnus, "Nonepileptic Uses of Gabapentin," <i>Epilepsia</i> , (40) (Suppl. 6): S66-S72 (1999).
B/D	C12	Saudek <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> , 1989, 321: 574.
B/D	C13	Sefton, "Implantable Pumps," <i>CRC Crit Ref Biomed. Eng.</i> 1987, 14:201.
B/D	C14	Verma <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Dev. Ind. Pharm.</i> , 2000, 26:695-708.

Examiner Signature	<i>B. Dent</i>	Date Considered	6-16-2005
--------------------	----------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.